FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4243864412> ?p ?o ?g. }

• W4243864412 endingPage "1636" @default.
• W4243864412 startingPage "1636" @default.
• W4243864412 abstract "Abstract Abstract 1636 Background: Radioimmunotherapy (RIT) is effective treatment for relapsed and refractory indolent lymphomas. Results in aggressive lymphomas such as diffuse large B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) have been less impressive, with lower response rates and short duration of response. We hypothesized that administration of the proteasome inhibitor bortezomib as a radiosensitizer in patients receiving RIT would be tolerable and potentially improve efficacy in both aggressive and indolent lymphomas. Methods: We performed a Phase 1 dose escalation study to evaluate the maximum tolerated dose (MTD) of bortezomib in combination with 131I-tositumomab. The study underwent review and was approved by each institution's Institutional Review Board. Dose escalation proceeded using a Time to Event-Continuous Reassessment Model (TiTE-CRM). Patients with relapsed or refractory DLBCL, MCL or indolent B cell non-Hodgkin's lymphoma were eligible if they had not undergone prior stem cell transplant, organ function was preserved, and bone marrow involvement by lymphoma was less than 25% of the intertrabecular space. Neutrophil count at least 1500/uL and platelet count at least 150 × 103/uL were required. A dosimetric dose of 131I-tositumomab was administered on day 1, followed by three whole body gamma camera scans for purposes of dose calculation and evaluation of biodistribution. After an initial cohort received a reduced whole-body dose of 50 cGy 131I-tositumomab, patients received RIT at the standard dose of 75 cGy on day 8. Patients were treated with escalating doses of bortezomib (0.3 to 1.2 mg/m2) on days 6, 10, 13, 16 and 20. Dose limiting toxicity (DLT) was defined as any grade 3 or 4 non-hematologic toxicity, or grade 4 hematologic toxicity. Results: The study has completed enrollment, with 25 patients having received study treatment. These include 8 patients with DLBCL, 5 with MCL, 11 with follicular lymphoma (FL), and one with marginal zone lymphoma (MZL). Median age is 68 (range 40–81). Median number of prior therapies is 2 (range 1–4), and all but one had received prior rituximab. Twenty-three patients are evaluable for response, while two patients have not yet undergone restaging. Twenty-four patients are evaluable for the primary endpoint of MTD. One treated patient was not evaluable for toxicity due to early progression of disease and need for further therapy prior to the end of the observation period. Of 24 patients evaluable, 4 experienced DLT (Table), all at dose level 5 (1.2 mg/m2). These events included grade 3 hyponatremia, herpes zoster, and grade 4 thrombocytopenia. Grade 3 hematologic toxicities included two patients with leukopenia, three with neutropenia, one with anemia, and five with thrombocytopenia. Dose level 4 (0.9 mg/m2 bortezomib, 75 cGy 131I-tositumomab) was well tolerated, and this dose was identified as the MTD. Fourteen of 23 (61%) patients evaluable for response have responded, including 3/8 with DLBCL, 3/5 with MCL, and 8/9 with FL. Ten patients have achieved complete remission, including one patient with DLBCL, one with MCL, and 8 with FL. At median follow up of 8 months, median progression free survival is 6 months, and seven patients (50% of responders) remain in remission at 2 to 28 months. Conclusions: Bortezomib can be safely administered in combination with 131I-tositumomab. Responses were seen in a majority of patients, including those with aggressive histology. The MTD has been defined as 0.9 mg/m2 bortezomib plus 75 cGy 131I-tositumomab. This strategy of radiosensitization using bortezomib shows promise, and efficacy should be further evaluated in a Phase 2 trial. Disclosures: Off Label Use: Azacitidine is approved for use in MDS. Discussion here is off label. Leonard:Glaxo SmithKline: Consultancy, Honoraria. Martin:Cephalon: Consultancy; Celgene: Consultancy; Millennium: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Pfizer: Research Funding; Genentech: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Lebovic:Genentech: Speakers Bureau. Coleman:Celgene Corp: Speakers Bureau. Kaminski:GlaxoSmithKline: Patents & Royalties, Research Funding." @default.
• W4243864412 created "2022-05-12" @default.
• W4243864412 creator A5002621242 @default.
• W4243864412 creator A5013974745 @default.
• W4243864412 creator A5014676729 @default.
• W4243864412 creator A5024592292 @default.
• W4243864412 creator A5033124013 @default.
• W4243864412 creator A5036507987 @default.
• W4243864412 creator A5036798940 @default.
• W4243864412 creator A5037882455 @default.
• W4243864412 creator A5040141808 @default.
• W4243864412 creator A5041794640 @default.
• W4243864412 creator A5045214991 @default.
• W4243864412 creator A5054231625 @default.
• W4243864412 creator A5065354635 @default.
• W4243864412 creator A5080126178 @default.
• W4243864412 creator A5080366682 @default.
• W4243864412 creator A5082720713 @default.
• W4243864412 date "2012-11-16" @default.
• W4243864412 modified "2023-10-07" @default.
• W4243864412 title "Phase 1 Study of Radiosensitization Using Bortezomib in Patients with Relapsed Non-Hodgkin's Lymphoma Receiving Radioimmunotherapy" @default.
• W4243864412 doi "https://doi.org/10.1182/blood.v120.21.1636.1636" @default.
• W4243864412 hasPublicationYear "2012" @default.
• W4243864412 type Work @default.
• W4243864412 citedByCount "1" @default.
• W4243864412 countsByYear W42438644122015 @default.
• W4243864412 crossrefType "journal-article" @default.
• W4243864412 hasAuthorship W4243864412A5002621242 @default.
• W4243864412 hasAuthorship W4243864412A5013974745 @default.
• W4243864412 hasAuthorship W4243864412A5014676729 @default.
• W4243864412 hasAuthorship W4243864412A5024592292 @default.
• W4243864412 hasAuthorship W4243864412A5033124013 @default.
• W4243864412 hasAuthorship W4243864412A5036507987 @default.
• W4243864412 hasAuthorship W4243864412A5036798940 @default.
• W4243864412 hasAuthorship W4243864412A5037882455 @default.
• W4243864412 hasAuthorship W4243864412A5040141808 @default.
• W4243864412 hasAuthorship W4243864412A5041794640 @default.
• W4243864412 hasAuthorship W4243864412A5045214991 @default.
• W4243864412 hasAuthorship W4243864412A5054231625 @default.
• W4243864412 hasAuthorship W4243864412A5065354635 @default.
• W4243864412 hasAuthorship W4243864412A5080126178 @default.
• W4243864412 hasAuthorship W4243864412A5080366682 @default.
• W4243864412 hasAuthorship W4243864412A5082720713 @default.
• W4243864412 hasConcept C126322002 @default.
• W4243864412 hasConcept C143998085 @default.
• W4243864412 hasConcept C159654299 @default.
• W4243864412 hasConcept C203014093 @default.
• W4243864412 hasConcept C2776146153 @default.
• W4243864412 hasConcept C2776364478 @default.
• W4243864412 hasConcept C2777478702 @default.
• W4243864412 hasConcept C2777525834 @default.
• W4243864412 hasConcept C2778367456 @default.
• W4243864412 hasConcept C2778559949 @default.
• W4243864412 hasConcept C2779338263 @default.
• W4243864412 hasConcept C2780007613 @default.
• W4243864412 hasConcept C2989005 @default.
• W4243864412 hasConcept C542903549 @default.
• W4243864412 hasConcept C71924100 @default.
• W4243864412 hasConceptScore W4243864412C126322002 @default.
• W4243864412 hasConceptScore W4243864412C143998085 @default.
• W4243864412 hasConceptScore W4243864412C159654299 @default.
• W4243864412 hasConceptScore W4243864412C203014093 @default.
• W4243864412 hasConceptScore W4243864412C2776146153 @default.
• W4243864412 hasConceptScore W4243864412C2776364478 @default.
• W4243864412 hasConceptScore W4243864412C2777478702 @default.
• W4243864412 hasConceptScore W4243864412C2777525834 @default.
• W4243864412 hasConceptScore W4243864412C2778367456 @default.
• W4243864412 hasConceptScore W4243864412C2778559949 @default.
• W4243864412 hasConceptScore W4243864412C2779338263 @default.
• W4243864412 hasConceptScore W4243864412C2780007613 @default.
• W4243864412 hasConceptScore W4243864412C2989005 @default.
• W4243864412 hasConceptScore W4243864412C542903549 @default.
• W4243864412 hasConceptScore W4243864412C71924100 @default.
• W4243864412 hasIssue "21" @default.
• W4243864412 hasLocation W42438644121 @default.
• W4243864412 hasOpenAccess W4243864412 @default.
• W4243864412 hasPrimaryLocation W42438644121 @default.
• W4243864412 hasRelatedWork W11761536 @default.
• W4243864412 hasRelatedWork W15259098 @default.
• W4243864412 hasRelatedWork W16338240 @default.
• W4243864412 hasRelatedWork W2106863 @default.
• W4243864412 hasRelatedWork W21424034 @default.
• W4243864412 hasRelatedWork W2409647 @default.
• W4243864412 hasRelatedWork W25010144 @default.
• W4243864412 hasRelatedWork W345234 @default.
• W4243864412 hasRelatedWork W21064296 @default.
• W4243864412 hasRelatedWork W26110756 @default.
• W4243864412 hasVolume "120" @default.
• W4243864412 isParatext "false" @default.
• W4243864412 isRetracted "false" @default.
• W4243864412 workType "article" @default.